Management Team

• Daniel M. Bradbury

  
  

  President and Chief Executive Officer

  
  

  Mr. Bradbury has been our Chief Executive Officer since March 2007, serving as President since June 2006 and as Chief Operating Officer since June 2003. He has served as a director since June 2006. He previously served as Executive Vice President from June 2000 until his promotion in June 2003. He joined Amylin in 1994 and has held officer-level positions in Corporate Development and Marketing during that time. Prior to joining Amylin, Mr. Bradbury spent ten years at SmithKline Beecham Pharmaceuticals, where he held a number of sales and marketing positions. He is a member of the Board of Directors of Illumina, Inc., BIOCOM, the Keck Graduate Institute’s Board of Trustees and the San Diego Regional Economic Development Corporation. Mr. Bradbury serves on the UCSD Rady School of Management’s Advisory Council, RAND Health Board of Advisors and University of Miami’s Innovation Corporate Advisory Council and the University of Miami's Diabetes Research Institute Corporate Advisory Council. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education.

• Mark G. Foletta

  
  

  Senior Vice President, Finance and Chief Financial Officer

  
  

  Mr. Foletta, one of our executive officers, has served as Senior Vice President, Finance and Chief Financial Officer since March 2006. He has previously served as Vice President, Finance and Chief Financial Officer from March 2000 to March 2006. Mr. Foletta previously served as a Principal of Triton Group Management, Inc. from 1997 to 2000. From 1986 to 1997, Mr. Foletta held a number of management positions with Intermark, Inc. and Triton Group Ltd., the most recent of which was Senior Vice President, Chief Financial Officer and Corporate Secretary. From 1982 to 1986, Mr. Foletta was with Ernst & Young, most recently serving as an Audit Manager. He is a director of Anadys Pharmaceuticals, Inc. Mr. Foletta earned his B.A. in Business Economics from the University of California, Santa Barbara. He is a Certified Public Accountant and a member of the Financial Executives Institute.

• Mark J. Gergen

  
  

  Senior Vice President, Corporate Development

  
  

  Mr. Gergen has served as our Senior Vice President of Corporate Development since August 2006 having previously served as Vice President of Business Development from May 2005 to August 2006. Prior to joining us, Mr. Gergen was an independent consultant to biotech and medical technology companies focusing on strategy, financing and corporate development. From 2003 to 2005, Mr. Gergen was Executive Vice President at CardioNet, Inc. He held various positions at Advanced Tissue Sciences, Inc. from 2000 to 2003 most recently as Chief Restructuring Officer and Acting CEO having previously served as Senior Vice President, Chief Financial and Development Officer and Vice President, Corporate Development, General Counsel and Secretary. From 1999 to 2000, Mr. Gergen was at Premier, Inc. and from 1994 to 1999 he held various positions with Medtronic, Inc. He held positions at Jostens, Inc. in corporate development and legal from 1990 to 1994. From 1986 to 1990 he held positions with several private law firms. Mr. Gergen serves on the Board of Directors of Aperio Technologies, Inc. a private venture-backed company. Mr. Gergen received his B.A. in Business Administration from Minot State University and his J.D. from the University of Minnesota Law School.

• Orville G. Kolterman, MD

  
  

  Senior Vice President, Chief Medical Officer

  
  

  Dr. Kolterman, one of our executive officers, has served as Senior Vice President, Chief Medical Officer since June 2010. He previously served as Senior Vice President, Research and Development since June 2008, as Senior Vice President, Development since March 2008, and as Senior Vice President, Regulatory Affairs since August 2005. Dr. Kolterman joined Amylin in 1992 and has held a number of officer-level positions in clinical and medical affairs during that time. Prior to joining Amylin, from 1983 to May 1992, he was Program Director of the General Clinical Research Center and Medical Director of the Diabetes Center, at the University of California, San Diego Medical Center. Since 1989, he has been Adjunct Professor of Medicine at UCSD. From 1978 to 1983, he was Assistant Professor of Medicine in the Endocrinology and Metabolism Division at the University of Colorado School of Medicine, Denver. He was a member of the Diabetes Control and Complications Trial (DCCT) Study Group and presently serves as a member of the Epidemiology of Diabetes Intervention and Complications (EDIC) Study Group. Dr. Kolterman also serves as a board member for Glysens, Inc., Viacyte, and the American Diabetes Association (ADA) Research Foundation and is a past-president of the California Affiliate of the ADA. Dr. Kolterman earned his M.D. from Stanford University School of Medicine.

• Harry J. Leonhardt

  
  

  Senior Vice President, Legal, Compliance and Corporate Secretary

  
  

  Mr. Leonhardt, one of our executive officers, has served as Senior Vice President, Legal, Compliance and Corporate Secretary since September 2011. He previously served as Vice President, Legal, Governance and Corporate Secretary since June 2010. Prior to that, he served as our Vice President, Chief Intellectual Property Counsel. Mr. Leonhardt has more than 28 years of corporate, intellectual property, litigation, executive management and mergers and acquisitions experience. Prior to joining us, Mr. Leonhardt served as Senior Vice President, General Counsel and Corporate Secretary of Senomyx, Inc. from September 2003 to September 2007. From February 2001 to September 2003 Mr. Leonhardt was Executive Vice President, General Counsel and Corporate Secretary of Genoptix, Inc. and from July 1996 to November 2000 he served as Vice President and then Senior Vice President, General Counsel and Corporate Secretary of Nanogen, Inc. From January 1990 through June 1996 Mr. Leonhardt served in various legal and management capacities at Allergan, Inc. Prior to that Mr. Leonhardt was an attorney with Lyon & Lyon LLP in Los Angeles where he represented a number of prominent pharmaceutical, biotechnology and consumer products companies. He also serves as a Special Master through the California State Bar. Mr. Leonhardt received his B.S. in Pharmacy from the University of the Sciences and his J.D. from the University of Southern California School of Law.

• Marcea Bland Lloyd

  
  

  Senior Vice President, Chief Administrative Officer and General Counsel

  
  

  Ms. Lloyd, one of our executive officers, has served as Senior Vice President, Chief Administrative Officer and General Counsel since June 2011. She previously served as Senior Vice President, Government & Corporate Affairs and General Counsel since February 2007. Prior to joining us, Ms. Lloyd served as Group Senior Vice President, Chief Administrative Officer, General Counsel and Secretary of VHA Inc. from November 2004 to February 2007. Previously, she served as VHA’s General Counsel and Secretary from May 1999 to November 2004. From 1993 to April 1999, Ms. Lloyd was Vice President and Assistant General Counsel of Medtronic, Inc. and served as Medtronic’s Assistant General Counsel from 1991 to 1993. From 1978 to 1991, Ms. Lloyd held various legal positions with Medtronic. Prior to joining Medtronic, Ms. Lloyd served as counsel to Pillsbury Company and Montgomery Ward & Co. and she taught Business Law at the University of Minnesota Business School. Ms. Lloyd is immediate past Chairperson of the Executive Leadership Foundation, a member of the board of directors for California Healthcare Institute (CHI) and is an associate of the Women Business Leaders of the United States Health Care Industry Foundation. She received a B.S./B.A. from Knox College and a J.D. from Northwestern University.

• Paul Marshall

  
  

  Senior Vice President, Operations

  
  

  Mr. Marshall has served as our Senior Vice President, Operations since December 2008. He previously served as Vice President, Operations from December 2006 to December 2008. Prior to joining Amylin, Mr. Marshall was Vice President of Corporate Manufacturing at Amgen Inc. From 2002 to 2005, Mr. Marshall served as Vice President of Global Manufacturing for Recombinant Proteins at the Bioscience Division of Baxter International, where he was responsible for five facilities with a VOS of over $1.3 Billion. From 1999 to 2002, he was Site Head of the Baxter International Thousand Oaks facility, where he supported increased sales through expansion of the facility into a Quad-Suite and Formulation, Fill and Finishing operation. He joined Creative BioMolecules in 1992, first as Head of Process Development and Clinical Manufacturing and then as Head of Operations, where he managed two manufacturing sites responsible for the production and commercial supply of the OP-1 implant device. From 1988 to 1992, Mr. Marshall held various management positions with Welgen Manufacturing Partnership (now Amgen, Rhode Island), Repligen Corporation, and Damon Biotech. He serves as a board member for Medicago, Inc., and is a member of ISPE and ASCB. Mr. Marshall received his M.S. and B.S. in Biology from the University of Massachusetts at Dartmouth, and performed three years of post-graduate work at Brown University in hematology and coagulation research.

• Vincent P. Mihalik

  
  

  Senior Vice President, Sales and Marketing and Chief Commercial Officer

  
  

  Mr. Mihalik joined Amylin Pharmaceuticals in January 2009 as Senior Vice President Sales and Marketing and Chief Commercial Officer. He has more than 20 years of commercial experience in the diabetes market, including marketing, sales and brand management. Prior to Amylin, he served as Vice President Global Brand Development and Endocrine Platform Team Leader at Eli Lilly & Company where he managed the second largest therapeutic area for the company and was responsible for product development to launch, lifecycle planning and commercialization since May 2004. From 2001 to 2004, he served as Business Unit head Diabetes Care at Lilly. Prior to Lilly, he was the Senior Vice President and General Manager for Lab Systems and Molecular Biochemicals at F. Hoffman-La Roche. From 1990 to 1998 at Boehringer Mannheim Group, he served in various management capacities including, Executive Vice President of Human Resources BM Global, Senior Vice President Global Marketing and Commercial Operations, Senior Vice President Strategic Business Development, and President, Patient Care Systems Division. He earned a Masters in Management from Kellogg School of Management, Northwestern University and a B.S. in Biology at the Pennsylvania State University.

• Christian Weyer, MD

  
  

  Senior Vice President, Research and Development

  
  

  Dr. Weyer, one of our executive officers, has served as Senior Vice President, Research and Development since June 2010, having previously served as Vice President, Medical Development. He previously served as Vice President of Corporate Development for Diabetes and Obesity from August 2008 to September 2009. Dr. Weyer has held leadership positions in Research, Clinical Development, Corporate Development, and Medical Affairs since joining Amylin in January 2001. Prior to joining us, Dr. Weyer was a Visiting Fellow with the National Institutes of Health, NIDDK, in Phoenix, AZ, from 1997-2000. In this role he conducted clinical research on the pathophysiology of obesity and type 2 diabetes in Pima Indians. He received his MD and clinical training at the Dept. of Metabolic Disorders, WHO Collaborating Center for Diabetes Treatment and Prevention, at the University of Düsseldorf, Germany. Dr. Weyer also holds a postdoctoral master’s degree in advanced clinical research from the University of California, San Diego, and currently serves on the program’s advisory board.